Novartis Global Pipeline

Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 200 projects in clinical development.

Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development.

For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2019.

Please note: the Novartis Pipeline data is updated quarterly.

Displaying 1 - 10 of 166 result(s)
Lead Indication

177Lu-NeoB

177Lu-NeoB

Multiple solid tumors

Oncology

Phase 1

>=2024

Radioligand therapy target GRPR

Lead Indication

177Lu-PSMA-617

177Lu-PSMA-617

Metastatic castration-resistant prostate cancer (mCRPC)

Oncology

Phase 3

2021

Targeted Radioligand Therapy (Targeted DNA destruction via beta-particle radiation)

Lead Indication

177Lu-PSMA-R2

177Lu-PSMA-R2

Prostate cancer

Oncology

Phase 1

>=2024

Radioligand therapy target PSMA

New Indication

177Lu-oxodotreotide

Lutathera®

Neuroendocrine tumors (GEP-NET 1L G3)

Oncology

Phase 3

2023

Targeted Radioligand Therapy (Targeted DNA destruction via beta-particle radiation)

Lead Indication

ABL001

asciminib

Chronic myeloid leukemia (CML), 3rd line

Oncology

Phase 3

2021

BCR-ABL inhibitor

New Indication

ACZ885

canakinumab

COVID-19 related induced respiratory disease

Immunology, Hepatology and Dermatology

Phase 3

IL-1b Inhibitor (Anti-interleukin-1ß monoclonal antibody)

New Indication

ACZ885

canakinumab

1st line non-small cell lung cancer (NSCLC)

Oncology

Phase 3

2021

IL-1b Inhibitor (Anti-interleukin-1ß monoclonal antibody)

New Indication

ACZ885

canakinumab

2nd line non-small cell lung cancer (NSCLC)

Oncology

Phase 3

2021

IL-1b Inhibitor (Anti-interleukin-1ß monoclonal antibody)

New Indication

ACZ885

canakinumab

Adjuvant non-small cell lung cancer (NSCLC)

Oncology

Phase 3

2023

IL-1b Inhibitor (Anti-interleukin-1ß monoclonal antibody)

New Indication

ADPT01

NIR178, LAG525, spartalizumab, canakinumab, capmatinib

Triple negative breast cancer (TNBC)

Oncology

Phase 1

LAG3 Inhibitor, PD1 Inhibitor (Anti-PD-1 monoclonal antibody)

Legend

Combination abbreviations:
fulv fulvestrant
tmx tamoxifen
gsn goserelin
NSAI Non-steroidal aromatase inhibitor
Taf Tafinlar® (dabrafenib)
Mek Mekinist® (trametinib)
a EU filing, approved in US.
b US filing, approved in EU.
c US filing, submitted in EU.
d US pending submission, approved in EU
e EU filing, submitted in US.

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.